دورية أكاديمية
أعرض في EDS

RANO 2.0 criteria: concepts applicable to the neuroradiologist's clinical practice.

التفاصيل البيبلوغرافية
العنوان: RANO 2.0 criteria: concepts applicable to the neuroradiologist's clinical practice.
المؤلفون: Sanvito F; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles, Los Angeles, California, USA., Castellano A; Neuroradiology Unit and CERMAC, IRCCS Ospedale San Raffaele Vita-Salute San Raffaele University, Milan, Italy., Cloughesy TF; UCLA Brain Tumor Program, Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Wen PY; Center For Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Ellingson BM; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles, Los Angeles, California, USA.
المصدر: Current opinion in oncology [Curr Opin Oncol] 2024 Jul 05. Date of Electronic Publication: 2024 Jul 05.
Publication Model: Ahead of Print
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9007265 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-703X (Electronic) Linking ISSN: 10408746 NLM ISO Abbreviation: Curr Opin Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: Philadelphia, PA : Lippincott Williams & Wilkins
Original Publication: Philadelphia, PA : Current Science, c1989-
مستخلص: Purpose of Review: The Response Assessment in Neuro-Oncology (RANO) 2.0 criteria aim at improving the standardization and reliability of treatment response assessment in clinical trials studying central nervous system (CNS) gliomas. This review presents the evidence supporting RANO 2.0 updates and discusses which concepts can be applicable to the clinical practice, particularly in the clinical radiographic reads.
Recent Findings: Updates in RANO 2.0 were supported by recent retrospective analyses of multicenter data from recent clinical trials. As proposed in RANO 2.0, in tumors receiving radiation therapy, the post-RT MRI scan should be used as a reference baseline for the following scans, as opposed to the pre-RT scan, and radiographic findings suggesting progression within three months after radiation therapy completion should be verified with confirmatory scans. Volumetric assessments should be considered, when available, especially for low-grade gliomas, and the evaluation of nonenhancing disease should have a marginal role in glioblastoma. However, the radiographic reads in the clinical setting also benefit from aspects that lie outside RANO 2.0 criteria, such as qualitative evaluations, patient-specific clinical considerations, and advanced imaging.
Summary: While RANO 2.0 criteria are meant for the standardization of the response assessment in clinical trials, some concepts have the potential to improve patients' management in the clinical practice.
(Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
References: Levin VA, Crafts DC, Norman DM, et al. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg 1977; 47:329–335.
Macdonald DR, Cascino TL, Schold SCJ, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277–1280.
Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28:1963–1972.
van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 2011; 12:583–593.
Ellingson BM, Wen PY, Cloughesy TF. Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurother J Am Soc Exp Neurother 2017; 14:307–320.
Wen PY, Van Den Bent MJ, Youssef G, et al. RANO 2.0: update to the Response Assessment in Neuro-Oncology criteria for high- and low-grade gliomas in adults. J Clin Oncol 2023; 41:5187–5199.
Youssef G, Rahman R, Bay C, et al. Evaluation of standard response assessment in neuro-oncology, modified response assessment in neuro-oncology, and immunotherapy response assessment in neuro-oncology in newly diagnosed and recurrent glioblastoma. J Clin Oncol 2023; 41:3160–3171.
Huang RY, Rahman R, Ballman KV, et al. The impact of T2/FLAIR evaluation per RANO criteria on response assessment of recurrent glioblastoma patients treated with bevacizumab. Clin Cancer Res 2016; 22:575–581.
Berntsen EM, Stensjøen AL, Langlo MS, et al. Volumetric segmentation of glioblastoma progression compared to bidimensional products and clinical radiological reports. Acta Neurochir (Wien) 2020; 162:379–387.
D’Arco F, O’Hare P, Dashti F, et al. Volumetric assessment of tumor size changes in pediatric low-grade gliomas: feasibility and comparison with linear measurements. Neuroradiology 2018; 60:427–436.
Ellingson BM, Kim GHJ, Brown M, et al. Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in nonenhancing diffuse gliomas: evidence from a phase I trial of ivosidenib. Neuro Oncol 2022; 24:770–778.
Dempsey MF, Condon BR, Hadley DM. Measurement of tumor ‘size’ in recurrent malignant glioma: 1D, 2D, or 3D? AJNR Am J Neuroradiol 2005; 26:770–776.
Blomstergren A, Rydelius A, Abul-Kasim K, et al. Evaluation of reproducibility in MRI quantitative volumetric assessment and its role in the prediction of overall survival and progression-free survival in glioblastoma. Acta Radiol 2019; 60:516–525.
Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021; 18:170–186.
Shigemoto Y, Sato N, Kimura Y, et al. Postoperative changes in the brain: assessment with serial T2WI/FLAIR MR images in nonneoplastic patients. Epilepsy Res 2019; 154:149–151.
Wakai S, Andoh Y, Ochiai C, et al. Postoperative contrast enhancement in brain tumors and intracerebral hematomas: CT study. J Comput Assist Tomogr 1990; 14:267–271.
Sato N, Bronen RA, Sze G, et al. Postoperative changes in the brain: MR imaging findings in patients without neoplasms. Radiology 1997; 204:839–846.
Carr CM, Benson JC, DeLone DR, et al. Intracranial long-term complications of radiation therapy: an image-based review. Neuroradiology 2021; 63:471–482.
Weinberg BD, Gore A, Shu H-KG, et al. Management-based structured reporting of posttreatment glioma response with the brain tumor reporting and data system. J Am Coll Radiol 2018; 15:767–771.
Zhang JY, Weinberg BD, Hu R, et al. Quantitative improvement in brain tumor MRI through structured reporting (BT-RADS). Acad Radiol 2020; 27:780–784.
Essien M, Cooper ME, Gore A, et al. Interrater agreement of BT-RADS for evaluation of follow-up MRI in treated primary brain tumor patients. AJNR Am J Neuroradiol 2024; ajnr.A8322 doi: 10.3174/ajnr.A8322. [Epub ahead of print]. (PMID: 10.3174/ajnr.A8322.)
Ellingson BM, Chung C, Pope WB, et al. Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol 2017; 134:495–504.
Ali FS, Arevalo O, Zorofchian S, et al. Cerebral radiation necrosis: incidence, pathogenesis, diagnostic challenges, and future opportunities. Curr Oncol Rep 2019; 21:66.
Cairncross JG, Macdonald DR, Pexman JH, Ives FJ. Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology 1988; 38:724–726.
Minamikawa S, Kono K, Nakayama K, et al. Glucocorticoid treatment of brain tumor patients: changes of apparent diffusion coefficient values measured by MR diffusion imaging. Neuroradiology 2004; 46:805–811.
Kural C, Atac GK, Tehli O, et al. The evaluation of the effects of steroid treatment on the tumor and peritumoral edema by DWI and MR spectroscopy in brain tumors. Neurol Neurochir Pol 2018; 52:495–504.
Henriksen OM, Del Mar Álvarez-Torres M, Figueiredo P, et al. High-grade glioma treatment response monitoring biomarkers: a position statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 1: Perfusion and diffusion techniques. Front Oncol 2022; 12:810263.
Booth TC, Wiegers EC, Warnert EAH, et al. High-grade glioma treatment response monitoring biomarkers: a position statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 2: Spectroscopy, chemical exchange saturation. Front Oncol 2021; 11:811425.
Gu X, He X, Wang H, et al. Dynamic susceptibility contrast-enhanced perfusion-weighted imaging in differentiation between recurrence and pseudoprogression in high-grade glioma: a meta-analysis. J Comput Assist Tomogr 2024; 48:303–310.
Alsulami TA, Hyare H, Thomas DL, Golay X. The value of arterial spin labelling (ASL) perfusion MRI in the assessment of posttreatment progression in adult glioma: a systematic review and meta-analysis. Neuro Oncol Adv 2023; 5:vdad122.
Patel P, Baradaran H, Delgado D, et al. MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis. Neuro Oncol 2017; 19:118–127.
Taylor C, Ekert JO, Sefcikova V, et al. Discriminators of pseudoprogression and true progression in high-grade gliomas: a systematic review and meta-analysis. Sci Rep 2022; 12:13258.
Dagher R, Gad M, da Silva de Santana P, et al. Umbrella review and network meta-analysis of diagnostic imaging test accuracy studies in differentiating between brain tumor progression versus pseudoprogression and radionecrosis. J Neurooncol 2024; 166:1–15.
Schlürmann T, Waschulzik B, Combs S, et al. Utility of Amino Acid PET in the differential diagnosis of recurrent brain metastases and treatment-related changes: a meta-analysis. J Nucl Med 2023; 64:816–821.
Ellingson BM, Sanvito F, Cloughesy TF, et al. A Neuroradiologist's guide to operationalizing the response assessment in neuro-oncology (RANO) criteria version 2.0 for gliomas in adults. AJNR Am J Neuroradiol 2024; ajnr.A8396 doi: 10.3174/ajnr.A8396. [Epub ahead of print]. (PMID: 10.3174/ajnr.A8396.)
معلومات مُعتمدة: R01 CA270027 United States CA NCI NIH HHS; R01 CA279984 United States CA NCI NIH HHS
تواريخ الأحداث: Date Created: 20240716 Latest Revision: 20240719
رمز التحديث: 20240719
DOI: 10.1097/CCO.0000000000001077
PMID: 39011735
قاعدة البيانات: MEDLINE
الوصف
تدمد:1531-703X
DOI:10.1097/CCO.0000000000001077